title: [The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain].
abstract: BACKGROUND
  Despite the recent discovery of the potential mechanisms underlying the analgesic effects of cannabis, few clinical studies have so far assessed its analgesic effects, notably in the treatment of chronic non-malignant pain. All the studies used administration of cannabis alone. The aim of this open, pilot, study was to assess the efficacy and side effect profile of oral dronabinol (tetrahydrocannabinol - THC) in the treatment of refractory neuropathic pain.
  
  
  METHODS
  Seven patients (3 women/4 men), aged 60 +/- 14 years, suffering from chronic refractory neuropathic pain, received oral THC titrated to the maximum dose of 25 mg/day (mean dose: 15 +/- 6 mg), during an average of 55,4 days (range: 13-128). Various components of pain (continuous, paroxysmal and brush-induced allodynia) were assessed using VAS scores. Health-related Quality of Life (HRQL) was evaluated using the Brief Pain Inventory, and the Hospital Anxiety and Depression scale was used to measure depression and anxiety.
  
  
  RESULTS
  THC did not induce significant effect on the various pain, HRQL and anxiety and depression scores. Numerous side effects (notably sedation and asthenia) were observed in 5 patients out of 7, requiring premature discontinuation of the drug in 3 patients.
  
  
  CONCLUSIONS
  The present study did not reveal any significant efficacy of THC in a small cohort of patients with chronic refractory neuropathic pain, but underlined the unfavorable side effect profile of the drug. These results may partly relate to the fact that oral dronabinol exhibits a poor therapeutic ratio (efficacy at the price of side effects). The development of new and better tolerated cannabinoids is warranted.
authors.affiliation: Service de pharmacie, Hôpital Ambroise Paré, Boulogne, France. sabine.gnamien@apr-aphop-paris.fr
authors.forename: Sabine
authors.initials: S
authors.lastname: Clermont-Gnamien
authors.forename: Sophie
authors.initials: S
authors.lastname: Atlani
authors.forename: Nadine
authors.initials: N
authors.lastname: Attal
authors.forename: Franck
authors.initials: F
authors.lastname: Le Mercier
authors.forename: Frédéric
authors.initials: F
authors.lastname: Guirimand
authors.forename: Louis
authors.initials: L
authors.lastname: Brasseur
mesh_terms: D000368:Aged; D000700:Analgesics / Q000008:administration & dosage / Q000627:therapeutic use; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001007:Anxiety / Q000175:diagnosis; D003627:Data Interpretation, Statistical; D003863:Depression / Q000175:diagnosis; D013759:Dronabinol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009437:Neuralgia / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D010146:Pain / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D010147:Pain Measurement; D010865:Pilot Projects; D011115:Polyneuropathies / Q000188:drug therapy; D011788:Quality of Life; D011795:Surveys and Questionnaires
chemical_list: D000700:Analgesics; D018712:Analgesics, Non-Narcotic; D013759:Dronabinol